secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-05-12T20:10:53+00:00
Accession:  0001104659-26-059392
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction
--------------------------------------------------------------------------------

- Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.
- Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.
- Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.
- FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.
- Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/0001104659-26-059392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer